Reported Saturday, Vera Therapeutics Presented 72-week EGFR Stabilization And Rapid Hematuria Improvement In Phase 2b ORIGIN Study Of Atacicept In IgAN At The 61st European Renal Association Congress
Reported Saturday, Vera Therapeutics Presented 72-week EGFR Stabilization And Rapid Hematuria Improvement In Phase 2b ORIGIN Study Of Atacicept In IgAN At The 61st European Renal Association Congress
週六報道，Vera Therapeutics在第61屆歐洲腎臟協會大會上發佈了爲期72周的表皮生長因子穩定和快速改善血尿的2b期IGAN研究
- 72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;
- Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo;
- 72 週數據與 iGaN 中的疾病變化一致，被選爲排名最佳的摘要；
- 在36周內，血尿狀況迅速持續改善，參與者的緩解比例明顯高於安慰劑；
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。